New Directions for Psychedelic Therapies Psilocybin in Neurodegenerative Disease and Chronic Illness
INSIGHT 2023 Replay from Therapy Track:
Prof. Dr. Albert Garcia-Romeu
Assistant Professor of Psychiatry and Behavioral Sciences,
Johns Hopkins University School of Medicine
This presentation explores exciting new frontiers in psychedelic science, highlighting two pilot studies investigating psilocybin-assisted therapy for under-researched conditions. The first study examines the effects of psilocybin on depression in individuals with Mild Cognitive Impairment (MCI) or early-stage Alzheimer’s Disease (AD), where traditional antidepressants often fail to alleviate neuropsychiatric symptoms like apathy and low mood. The second study focuses on post-treatment Lyme Disease—a condition marked by persistent fatigue, pain, and cognitive impairment—for which no effective treatment currently exists. Preliminary data and clinical rationale will be shared, along with a broader discussion on expanding the use of psychedelic-assisted treatments in diverse medical populations.
INSIGHT 2023 Replay from Therapy Track:
Prof. Dr. Albert Garcia-Romeu
Assistant Professor of Psychiatry and Behavioral Sciences,
Johns Hopkins University School of Medicine
This presentation explores exciting new frontiers in psychedelic science, highlighting two pilot studies investigating psilocybin-assisted therapy for under-researched conditions. The first study examines the effects of psilocybin on depression in individuals with Mild Cognitive Impairment (MCI) or early-stage Alzheimer’s Disease (AD), where traditional antidepressants often fail to alleviate neuropsychiatric symptoms like apathy and low mood. The second study focuses on post-treatment Lyme Disease—a condition marked by persistent fatigue, pain, and cognitive impairment—for which no effective treatment currently exists. Preliminary data and clinical rationale will be shared, along with a broader discussion on expanding the use of psychedelic-assisted treatments in diverse medical populations.
Comments